Detection of Peritoneal Metastasis of Gastric Cancer by Liquid Biopsy in Peripheral Blood: A Prospective Study

Cancer Clinical Trial

Official title:

Detection of Peritoneal Metastasis of Gastric Cancer by Liquid Biopsy in Peripheral Blood: A Prospective Study

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05347524
• Other study ID #: B2022-081R
• Status: Recruiting
• Start date: March 1, 2022
• Est. completion date: June 30, 2030

Study information

• Verified date: April 2022
• Source: Shanghai Zhongshan Hospital
• Contact: Yihong Sun, Ph. D
• Phone: +86-021-65642662
• Email: sun.yihong[@]zs-hospital.sh.cn
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This study is a prospective, multi-omics, observational study aimed at detecting peritoneal metastasis of gastric cancer by combined assays for methylation of cell-free DNA (cfDNA) and other blood-based biomarkers. The study will enroll 384 participants with gastric cancer.

Description:

Peritoneal metastasis (PM) in gastric cancer is associated with a poor prognosis. Laparoscopy with cytology is performed to evaluate for peritoneal spread when considering chemoradiation or surgery. However, the laparoscopy is invasive and the sensitivity of computed tomography (CT) scan is poor for detecting PM. Therefore, it is necessary to evaluate the feasibility of cfDNA methylation and other blood-based biomarkers for the PM diagnosis. The study will enroll 384 participants with gastric cancer. Baseline blood and diagnosis of PM by laparoscopy with cytology will be collected. Participants with PM will be defined as the case arm and participants without PM will be defined as the control arm. A PM diagnostic model will be developed.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 384
• Est. completion date: June 30, 2030
• Est. primary completion date: December 31, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 74 Years

Eligibility

Inclusion Criteria:

• Inclusion Criteria for Case Arm Participants:

1. Age 18-74 years at the day of consenting to the study.

2. Able to provide a written informed consent.

3. No prior cancer treatment (local or systematic) with either of the following:

A. Pathologically confirmed gastric cancer diagnosis within 42 days prior to blood draw. B. High suspicious for cancer diagnosis by imaging tests or other routine clinical examinations, with confirmed pathological cancer diagnosis within 42 days after the blood draw.

4. Diagnosis of peritoneal metastasis by laparoscopy with cytology.

• Inclusion Criteria for Control Arm Participants:

1. Age 18-74 years at the day of consenting to the study.

2. Able to provide a written informed consent.

3. No prior cancer treatment (local or systematic) with either of the following:

A. Pathologically confirmed gastric cancer diagnosis within 42 days prior to blood draw. B. High suspicious for cancer diagnosis by imaging tests or other routine clinical examinations, with confirmed pathological cancer diagnosis within 42 days after the blood draw.

4. No peritoneal metastasis detected by laparoscopy with cytology.

Exclusion Criteria:

• Exclusion Criteria for All Participants:

1. Insufficient qualified blood samples.

2. During pregnancy or lactation.

3. Recipient of organ transplant or prior non-autologous (allogeneic) bone marrow or stem cell transplant.

4. Recipient of blood transfusion within 7 days prior to blood draw.

5. Recipient of anti-tumor drugs to treat non-cancer diseases within 30 days prior to blood draw.

6. With other known malignant tumors or multiple primary tumors.

• Exclusion Criteria for Control Arm Participants:

1. Insufficient qualified blood samples.

2. During pregnancy or lactation.

3. Recipient of organ transplant or prior non-autologous (allogeneic) bone marrow or stem cell transplant.

4. Recipient of blood transfusion within 7 days prior to blood draw.

5. Recipient of anti-tumor drugs to treat non-cancer diseases within 30 days prior to blood draw.

6. With other known malignant tumors or multiple primary tumors.

Related Conditions & MeSH terms

• Cancer
• Neoplasm Metastasis

Intervention

Other:
• Baseline blood draw and blood-based biomarkers analyses
Baseline blood draw and blood-based biomarkers analyses

Locations

Country	Name	City	State
China	ZhongShan Hospital, Fudan university, Shanghai, China	Shanghai	Shanghai

Sponsors (2)

Lead Sponsor	Collaborator
Shanghai Zhongshan Hospital	Guangzhou Burning Rock Bioengineering Ltd

Country where clinical trial is conducted

China, 

References & Publications (23)

Allen CJ, Newhook TE, Vreeland TJ, Das P, Minsky BD, Blum M, Song S, Ajani J, Ikoma N, Mansfield PF, Roy-Chowdhuri S, Badgwell BD. Yield of peritoneal cytology in staging patients with gastric and gastroesophageal cancer. J Surg Oncol. 2019 Dec;120(8):1350-1357. doi: 10.1002/jso.25729. Epub 2019 Oct 14. — View Citation

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018 Nov;68(6):394-424. doi: 10.3322/caac.21492. Epub 2018 Sep 12. Erratum in: CA Cancer J Clin. 2020 Jul;70(4):313. — View Citation

Chen M, Zhao H. Next-generation sequencing in liquid biopsy: cancer screening and early detection. Hum Genomics. 2019 Aug 1;13(1):34. doi: 10.1186/s40246-019-0220-8. Review. — View Citation

Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J. Cancer statistics in China, 2015. CA Cancer J Clin. 2016 Mar-Apr;66(2):115-32. doi: 10.3322/caac.21338. Epub 2016 Jan 25. — View Citation

Guo S, Diep D, Plongthongkum N, Fung HL, Zhang K, Zhang K. Identification of methylation haplotype blocks aids in deconvolution of heterogeneous tissue samples and tumor tissue-of-origin mapping from plasma DNA. Nat Genet. 2017 Apr;49(4):635-642. doi: 10.1038/ng.3805. Epub 2017 Mar 6. — View Citation

Haber DA, Velculescu VE. Blood-based analyses of cancer: circulating tumor cells and circulating tumor DNA. Cancer Discov. 2014 Jun;4(6):650-61. doi: 10.1158/2159-8290.CD-13-1014. Epub 2014 May 6. Review. — View Citation

Harada H, Soeno T, Nishizawa N, Washio M, Sakuraya M, Ushiku H, Niihara M, Hosoda K, Kumamoto Y, Naitoh T, Sangai T, Hiki N, Yamashita K. Prospective study to validate the clinical utility of DNA diagnosis of peritoneal fluid cytology test in gastric cancer. Cancer Sci. 2021 Apr;112(4):1644-1654. doi: 10.1111/cas.14850. Epub 2021 Feb 27. — View Citation

Hu XY, Ling ZN, Hong LL, Yu QM, Li P, Ling ZQ. Circulating methylated THBS1 DNAs as a novel marker for predicting peritoneal dissemination in gastric cancer. J Clin Lab Anal. 2021 Sep;35(9):e23936. doi: 10.1002/jcla.23936. Epub 2021 Aug 13. — View Citation

Juzenas S, Venkatesh G, Hübenthal M, Hoeppner MP, Du ZG, Paulsen M, Rosenstiel P, Senger P, Hofmann-Apitius M, Keller A, Kupcinskas L, Franke A, Hemmrich-Stanisak G. A comprehensive, cell specific microRNA catalogue of human peripheral blood. Nucleic Acids Res. 2017 Sep 19;45(16):9290-9301. doi: 10.1093/nar/gkx706. — View Citation

Kinoshita J, Fushida S, Harada S, Makino I, Nakamura K, Oyama K, Fujita H, Ninomiya I, Fujimura T, Kayahara M, Ohta T. Type IV collagen levels are elevated in the serum of patients with peritoneal dissemination of gastric cancer. Oncol Lett. 2010 Nov;1(6):989-994. Epub 2010 Sep 23. — View Citation

Klutstein M, Nejman D, Greenfield R, Cedar H. DNA Methylation in Cancer and Aging. Cancer Res. 2016 Jun 15;76(12):3446-50. doi: 10.1158/0008-5472.CAN-15-3278. Epub 2016 Jun 2. Review. — View Citation

Liu MC, Oxnard GR, Klein EA, Swanton C, Seiden MV; CCGA Consortium. Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA. Ann Oncol. 2020 Jun;31(6):745-759. doi: 10.1016/j.annonc.2020.02.011. Epub 2020 Mar 30. — View Citation

Meng H, Cao Y, Qin J, Song X, Zhang Q, Shi Y, Cao L. DNA methylation, its mediators and genome integrity. Int J Biol Sci. 2015 Apr 8;11(5):604-17. doi: 10.7150/ijbs.11218. eCollection 2015. Review. — View Citation

Morgan AE, Davies TJ, Mc Auley MT. The role of DNA methylation in ageing and cancer. Proc Nutr Soc. 2018 Nov;77(4):412-422. doi: 10.1017/S0029665118000150. Epub 2018 Apr 30. Review. — View Citation

Pantel K, Alix-Panabières C. Liquid biopsy and minimal residual disease - latest advances and implications for cure. Nat Rev Clin Oncol. 2019 Jul;16(7):409-424. doi: 10.1038/s41571-019-0187-3. Review. — View Citation

Qi C, Li P, Hu Y, et al. The ctDNA in peritoneal effusion of advanced gastric cancer for auxiliary diagnosis of peritoneal metastasis. Journal of Clinical Oncology. 2019/05/20 2019;37(15_suppl):e15516-e15516. doi:10.1200/JCO.2019.37.15_suppl.e15516

Rijken A, Lurvink RJ, Luyer MDP, Nieuwenhuijzen GAP, van Erning FN, van Sandick JW, de Hingh IHJT. The Burden of Peritoneal Metastases from Gastric Cancer: A Systematic Review on the Incidence, Risk Factors and Survival. J Clin Med. 2021 Oct 23;10(21). pii: 4882. doi: 10.3390/jcm10214882. Review. — View Citation

Shimura T, Toden S, Kandimalla R, Toiyama Y, Okugawa Y, Kanda M, Baba H, Kodera Y, Kusunoki M, Goel A. Genomewide Expression Profiling Identifies a Novel miRNA-based Signature for the Detection of Peritoneal Metastasis in Patients With Gastric Cancer. Ann Surg. 2021 Nov 1;274(5):e425-e434. doi: 10.1097/SLA.0000000000003647. — View Citation

So JBY, Kapoor R, Zhu F, Koh C, Zhou L, Zou R, Tang YC, Goo PCK, Rha SY, Chung HC, Yoong J, Yap CT, Rao J, Chia CK, Tsao S, Shabbir A, Lee J, Lam KP, Hartman M, Yong WP, Too HP, Yeoh KG. Development and validation of a serum microRNA biomarker panel for detecting gastric cancer in a high-risk population. Gut. 2021 May;70(5):829-837. doi: 10.1136/gutjnl-2020-322065. Epub 2020 Oct 7. — View Citation

Thomassen I, van Gestel YR, van Ramshorst B, Luyer MD, Bosscha K, Nienhuijs SW, Lemmens VE, de Hingh IH. Peritoneal carcinomatosis of gastric origin: a population-based study on incidence, survival and risk factors. Int J Cancer. 2014 Feb 1;134(3):622-8. doi: 10.1002/ijc.28373. Epub 2013 Aug 5. — View Citation

Widschwendter M, Jones A, Evans I, Reisel D, Dillner J, Sundström K, Steyerberg EW, Vergouwe Y, Wegwarth O, Rebitschek FG, Siebert U, Sroczynski G, de Beaufort ID, Bolt I, Cibula D, Zikan M, Bjørge L, Colombo N, Harbeck N, Dudbridge F, Tasse AM, Knoppers BM, Joly Y, Teschendorff AE, Pashayan N; FORECEE (4C) Consortium. Epigenome-based cancer risk prediction: rationale, opportunities and challenges. Nat Rev Clin Oncol. 2018 May;15(5):292-309. doi: 10.1038/nrclinonc.2018.30. Epub 2018 Feb 27. Review. — View Citation

Wu R, Li Q, Wu F, Shi C, Chen Q. Comprehensive Analysis of CDC27 Related to Peritoneal Metastasis by Whole Exome Sequencing in Gastric Cancer. Onco Targets Ther. 2020 Apr 21;13:3335-3346. doi: 10.2147/OTT.S244351. eCollection 2020. — View Citation

Zhao D, Yue P, Wang T, Wang P, Song Q, Wang J, Jiao Y. Personalized analysis of minimal residual cancer cells in peritoneal lavage fluid predicts peritoneal dissemination of gastric cancer. J Hematol Oncol. 2021 Oct 12;14(1):164. doi: 10.1186/s13045-021-01175-2. — View Citation

* Note: There are 23 references in all — Click here to view all references

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Sensitivity and specificity of the cfDNA methylation-based model in detecting peritoneal metastasis of gastric cancer.		30 months
Primary	Sensitivity and specificity of a cfDNA methylation-based model, in combination with other biomarkers, for detecting peritoneal metastasis of gastric cancer.		30 months